Nuwellis reports 92% survival in children with AKI in ULTRA-Peds registry

Nuwellis (NUWE) announced findings from the ULTRA-Peds registry, a multi-center observational study examining the real-world use of the Aquadex System in children with acute kidney injury, fluid overload, or congenital kidney failure. The ULTRA-Peds registry enrolled 91 pediatric patients across eight U.S. centers, representing a comprehensive real-world dataset to date in this vulnerable population. Diagnoses included congenital heart disease, end-stage renal disease, and malignancy. Results demonstrated strong survival and procedural success: 92% of patients survived their Aquadex treatment course; 66% survived to hospital discharge; 86% of circuits completed their intended treatment course without interruption; Heparin anticoagulation was associated with longer circuit duration compared to bivalirudin. These findings show that Aquadex therapy is both feasible and well tolerated in critically ill children, a population with extremely limited treatment alternatives.